Your session is about to expire
← Back to Search
Other
Home Delivery of Cabenuva for HIV
N/A
Waitlist Available
Led By Jure Baloh, PhD
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 months
Awards & highlights
Study Summary
This trial is studying two ways to give the medication Cabenuva to people with HIV, either at the clinic or at home, to see which is better.
Who is the study for?
This trial is for adults over 18 with HIV who are getting Cabenuva injections at one of six clinics involved in the study. They must be able to consent and, if in the home delivery group, live within 40 miles of certain clinics. Pregnant or breastfeeding women are excluded.Check my eligibility
What is being tested?
The study compares two ways to deliver Cabenuva: at a clinic or at home. Each method will have 50 patients from Arkansas's outpatient HIV clinics, followed for 10 months to measure medication adherence and satisfaction.See study design
What are the potential side effects?
While specific side effects aren't listed here, generally Cabenuva may cause reactions like injection site pain, fever, fatigue, headache, muscle pain and possible allergic reactions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 10 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Medication adherence
Secondary outcome measures
Patient treatment satisfaction
Other outcome measures
Clinician perceptions of acceptability
Clinician perceptions of appropriateness
Clinician perceptions of feasibility
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Home visit armExperimental Treatment1 Intervention
Patient will receive Cabenuva injection at home
Group II: Clinic visit armActive Control1 Intervention
Patient will receive Cabenuva injection at the clinic
Find a Location
Who is running the clinical trial?
ViiV HealthcareIndustry Sponsor
359 Previous Clinical Trials
468,542 Total Patients Enrolled
University of ArkansasLead Sponsor
486 Previous Clinical Trials
150,352 Total Patients Enrolled
Jure Baloh, PhDPrincipal InvestigatorUniversity of Arkansas
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Clinic visit arm
- Group 2: Home visit arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is recruitment for this research endeavor still ongoing?
"Affirmative. According to the information on clinicaltrials.gov, this medical study initiated recruitment on March 7th 2022 and was last revised by researchers on October 20th 2022. The trial is looking for 100 participants at a single location."
Answered by AI
How many individuals are participating in the trial thus far?
"Affirmative. Clinical trial data published on clinicaltrials.gov demonstrates that this medical investigation, which was first released on March 7th 2022, is actively recruiting participants. The study requires 100 subjects to be recruited from a single site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger